SUMO2P17

Across TCGA pan-cancer cohorts, SUMO2P17 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of SUMO2P17’s most consistent transcriptional readouts.

The strongest signal is observed in kidney chromophobe (KICH), where SUMO2P17 RNA is repressed in tumor relative to normal tissue. In most cancer types SUMO2P17 is over-expressed in tumor, although a few such as KICH and THCA show the opposite, repressed pattern.

KICH, HNSC, and THCA are the cancer types where SUMO2P17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SUMO2P17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KICH	Female	All	−0.971	<.001	9	view →
HNSC	Male	All	+0.334	<.001	8	view →
THCA	All	All	−0.322	<.001	8	view →
BRCA	All	III,IV	+0.741	<.001	6	view →
LIHC	Male	All	+0.379	<.001	6	view →
BLCA	All	All	+0.365	.005	6	view →
LUSC	All	All	+0.425	<.001	5	view →
CHOL	Male	All	+0.508	.001	4	view →
STAD	Male	All	+0.396	.003	4	view →
KIRC	All	II,III,IV	−0.183	.008	3	view →
COAD	All	II,III,IV	+0.372	.022	2	view →
LUAD	Female	All	+0.303	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

SUMO2P17–KICH

Open the KICH breakdown →